Ipsen

IPN

FR0010259150

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

2024-05-27 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

114.1 EUR

Average target price

125.2 EUR

Spread / Average Target

+9.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+7.51%	10.07B
ELI LILLY AND COMPANY	+31.66%	699B
NOVO NORDISK A/S	+25.97%	571B
JOHNSON & JOHNSON	-4.26%	364B
MERCK & CO., INC.	+18.08%	326B
ABBVIE INC.	+2.10%	286B
ASTRAZENECA PLC	+14.60%	236B
NOVARTIS AG	+4.45%	198B
ROCHE HOLDING AG	-11.82%	194B
PFIZER, INC.	-4.31%	154B

Other Pharmaceuticals

Real-time Euronext Paris Other stock markets 10:21:23 2024-05-02 am EDT			5-day change	1st Jan Change
116 ^EUR	+1.67%		+4.13%	+7.51%

01:58pm	Ipsen Announces Executive Changes	CI
08:58am	Ipsen: new President for North America	CF

Ipsen Announces Executive Changes	07:58am	CI
Ipsen: new President for North America	02:58am	CF
IPSEN : Better-than-expected Q1; guidance unchanged	Apr. 24
Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	Apr. 24
Ipsen: sales up 11% in Q1	Apr. 24	CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI
Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
IPSEN : UBS reiterates its buy recommendation	Feb. 14	CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults	Feb. 13	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
Transcript : Ipsen S.A., 2023 Earnings Call, Feb 08, 2024	Feb. 08
Ipsen: 13% drop in annual EPS	Feb. 08	CF